Aduro BioTech's Series B - III Round

Aduro BioTech raised a round of funding on September 10, 2013. Investors include Morningside Group (晨兴集团).

Aduro is advancing multiple therapeutic and prophylactic vaccines for cancer and infectious diseases based on its attenuated Listeria monocytogenes vaccine platforms. The company is also advancing a n…

Articles about Aduro BioTech's Series B - III Round: